BioCardia Files 8-K: Other Events & Financials
Ticker: BCDA · Form: 8-K · Filed: Sep 9, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B, $7.2 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: BCDA
TL;DR
BioCardia dropped an 8-K on 9/9 covering 9/3 events and financials. Check it out.
AI Summary
BioCardia, Inc. filed an 8-K on September 9, 2024, reporting on other events and financial statements. The filing indicates a report date of September 3, 2024, and includes information about the company's principal executive offices located at 320 Soquel Way, Sunnyvale, California.
Why It Matters
This 8-K filing provides an update on BioCardia's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on other events and financial statements, with no immediate indication of significant risk.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- September 3, 2024 (date) — Earliest event reported date
- September 9, 2024 (date) — Date of report
- 320 Soquel Way, Sunnyvale, California 94085 (location) — Principal executive offices address
FAQ
What is the primary purpose of this 8-K filing for BioCardia, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 3, 2024.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on September 9, 2024.
What is the address of BioCardia, Inc.'s principal executive offices?
The address of BioCardia, Inc.'s principal executive offices is 320 Soquel Way, Sunnyvale, California 94085.
What is BioCardia, Inc.'s Commission File Number?
BioCardia, Inc.'s Commission File Number is 001-38999.
What is the SIC code for BioCardia, Inc. and what does it represent?
The SIC code for BioCardia, Inc. is 2836, which represents 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-09-09 16:06:56
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
- $7.2 million — s release announcing the closing of its $7.2 million public offering on September 3, 2024. A
Filing Documents
- bcda20240909_8k.htm (8-K) — 26KB
- ex_722602.htm (EX-99.1) — 9KB
- 0001437749-24-028756.txt ( ) — 167KB
- bcda-20240903.xsd (EX-101.SCH) — 3KB
- bcda-20240903_def.xml (EX-101.DEF) — 11KB
- bcda-20240903_lab.xml (EX-101.LAB) — 15KB
- bcda-20240903_pre.xml (EX-101.PRE) — 11KB
- bcda20240909_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 9, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the closing of its $7.2 million public offering on September 3, 2024. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated September 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 9, 2024